Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein
P-glycoprotein (P-gp), also known as ABCB1, is a cell membrane transporter that mediates the efflux of chemically dissimilar amphipathic drugs and confers resistance to chemotherapy in most cancers. Homologous transmembrane helices (TMHs) 6 and 12 of human P-gp connect the transmembrane domains with...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 117; no. 47; pp. 29609 - 29617 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
24.11.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | P-glycoprotein (P-gp), also known as ABCB1, is a cell membrane transporter that mediates the efflux of chemically dissimilar amphipathic drugs and confers resistance to chemotherapy in most cancers. Homologous transmembrane helices (TMHs) 6 and 12 of human P-gp connect the transmembrane domains with its nucleotide-binding domains, and several residues in these TMHs contribute to the drug-binding pocket. To investigate the role of these helices in the transport function of P-gp, we substituted a group of 14 conserved residues (seven in both TMHs 6 and 12) with alanine and generated a mutant termed 14A. Although the 14A mutant lost the ability to pump most of the substrates tested out of cancer cells, surprisingly, it acquired a new function. It was able to import four substrates, including rhodamine 123 (Rh123) and the taxol derivative flutax-1. Similar to the efflux function of wild-type P-gp, we found that uptake by the 14A mutant is ATP hydrolysis-, substrate concentration-, and time-dependent. Consistent with the uptake function, the mutant P-gp also hypersensitizes HeLa cells to Rh123 by 2- to 2.5-fold. Further mutagenesis identified residues from both TMHs 6 and 12 that synergistically form a switch in the central region of the two helices that governs whether a given substrate is pumped out of or into the cell. Transforming P-gp or an ABC drug exporter from an efflux transporter into a drug uptake pump would constitute a paradigm shift in efforts to overcome cancer drug resistance. |
---|---|
Bibliography: | Author contributions: A.S., S.L., E.E.C., and S.V.A. designed research; A.S., S.L., M.M., E.E.C., and B.A. performed research; A.S., S.L., M.M., E.E.C., and B.A. analyzed data; S.R.D. carried out in silico studies including molecular dynamics simulations; A.S., S.L., M.M.G., S.R.D., and S.V.A. wrote the paper; and S.V.A. supervised the study. Reviewers: B.B., University of Kentucky; and C.V.S., Purdue University. Contributed by Michael M. Gottesman, September 30, 2020 (sent for review July 31, 2020; reviewed by Björn Bauer and Cynthia Vianne Stauffacher) |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.2016270117 |